1.
Chinese Journal of Gastroenterology
;
(12): 626-629, 2018.
Artículo
en Chino
| WPRIM
| ID: wpr-698216
RESUMEN
Perianal fistulizing Crohn's disease (pfCD)often indicates aggressive and refractory phenotype. Two-thirds of the patients with pfCD will relapse,so the treatment is really challenging. Currently,biological agents have made great progress. The application of biological agents such as infliximab brings new hope to the treatment of pfCD. This article reviewed the application of biological agents in treatment of pfCD.